Anti-Migraine Drugs Market

Adequate Supply of Medications during COVID-19 Pandemic Reduces Serious Migraine Triggers

Amid growing concerns about the impact of the novel coronavirus (COVID-19) on the global community, manufacturers in the anti-migraine drugs market are fortifying healthcare systems with steady supply chains. As suggested by the American Migraine Foundation, people living with migraine are considering stocking up medications, owing to volatile demand and supply. Individuals should work with their doctors and insurance companies to ensure adequate supply of their acute, preventive, and rescue medications.

Apart from maintaining adequate supply of medicines, companies in the anti migraine drugs market are educating individuals to consider alternatives to in-person doctor visits in order to limit the spread of coronavirus. Being mindful about diet and lifestyle habits is crucial during current challenging times. Alternate measures for reducing migraine triggers are important since even pharma companies are facing challenges in maintaining their workforce and API (Active Pharmaceutical Ingredient) supply.

Implantable Neurostimulation Systems Pose Stiff Competition to Drug Sales

New small molecule drug approvals are bolstering growth in the anti-migraine drugs market. These novel drugs block pain transmission in the trigeminovascular system of adults who have migraine headaches with or without aura. Companies in the anti-migraine drugs market are increasing their marketing capabilities for Ubrogepant, also known as Ubrelvy, which is an oral calcitonin gene–related peptide receptor antagonist. As such, pharma companies are increasing their production capabilities in oral medications meant for acute treatment of migraine. These drugs are emerging as alternatives to opioids, ergot, triptans, and ibuprofen.

Moreover, innovations in drug formulations are boosting market growth. However, alternate treatment methods such as implantable neurostimulation systems are posing as a stiff competition to the sales of drugs. Hence, pharma companies should diversify their manufacturing and R&D in implantable devices to gain competitive edge.

Migraine R&D Activities Receive Boost from Professional Athletes to Deliver Efficient Diagnosis

Funding schemes are encouraging manufacturers in the anti-migraine drugs market to focus on R&D activities. The Association of Migraine Disorders is raising funds to conduct bold migraine research activities by supporting education and awareness about migraine. Provisions of seed funding and stimulating collaborative networking are some of the key drivers that are contributing toward the expansion of the anti-migraine drugs market. Easy accessibility toward education and enhanced visibility of migraine disease through social media are helping patients receive medical treatment.

Healthcare associations are collaborating with professional athletes to attract donations for migraine research. This trend has become important since a significant percentage of the world population is yet to receive diagnosis for migraine. Research activities for migraine treatment are increasingly becoming important as people living with migraine face difficulties and discrimination at workplaces.

Acute Interventions Including Nonspecific Analgesic Therapies Offer Desired Pain Relief

Migraine headaches remain a significant medical concern for many people. Hence, manufacturers in the anti-migraine drugs market are innovating in calcitonin gene-related peptide (CGRP) pathways to deliver efficient diagnosis. CGRP inhibitors are considered as the gold standard for migraine treatment. As such, people are becoming aware that Cephalalgia is also classified as migraine and needs medical care. However, existing treatments are often deficient in pain relief and induce adverse effects in people. In order to overcome these issues, pharma companies in the anti-migraine drugs market are increasing the availability of acute interventions such as nonspecific analgesic therapies and migraine-specific medications.

Pharma companies are boosting their production output in non-steroidal anti-inflammatory drugs, ergotamine derivatives, and anti-emetic medications to increase patient accessibility toward medications. It has been found that triptans are better tolerated than ergot alkaloids.

Increased Focus on Clinical Trials Help Produce Safe and Well Tolerated Drugs

Since acutely acting drugs carry the risk of overuse, CGRP inhibitors are a new class of drugs that hold promising potentials to treat frequent, episodic, and chronic migraine. Due to the large molecule size of CGRP pathways, these drugs are administered parenterally. It has been found that these drugs are capable of diminishing the migraine frequency, thus resulting in patient satisfaction and improved quality of life. CGRP inhibitors are being highly publicized for reducing medication usage and migraine attacks for days.

Companies in the anti-migraine drugs market are producing Erenumab (AMG 334), marketed as Aimovig, since it is approved by healthcare associations. They are tapping into incremental opportunities with the sales of fremazenumab and galcanezumab. Manufacturers are increasing their focus in clinical trials to introduce new class of migraine drugs. As such, the newly introduced CGRP antagonists are potentially safe and better tolerated in individuals.